Invivyd Inc. Announces New Clinical Study to Evaluate Monoclonal Antibody Therapy for Long COVID at RECOVER-TLC Workshop

Reuters
09/04
Invivyd Inc. Announces New Clinical Study to Evaluate Monoclonal Antibody Therapy for Long COVID at RECOVER-TLC Workshop

Invivyd, Inc. (Nasdaq: IVVD) has announced that the SPEAR Study Group has put forward a consensus recommendation for a clinical study design aimed at evaluating the effects of monoclonal antibody therapy on Long COVID. This proposed study, which centers on the use of anti-SARS-CoV-2 spike protein monoclonal antibodies, including Invivyd's VYD2311, will be presented at the Second Annual RECOVER-TLC Workshop, scheduled for September 9-10, 2025, in Bethesda, Maryland. The SPEAR Study Group's proposal reflects current evidence on the potential of monoclonal antibodies in treating Long COVID and identifies VYD2311 as a promising candidate. The study design is set to maintain high antiviral antibody titers over an extended period to suppress chronic infection potentially driving Long COVID. Drs. Amy Proal and David Putrino will present the study design for consideration by RECOVER-TLC, with Dr. Putrino scheduled to present the clinical study design on September 10, 2025, at 9:25 a.m. ET, followed by Dr. Proal's discussion on the antiviral landscape at 1:00 p.m. ET on the same day.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9523078-en) on September 04, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10